A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

Inclusion Criteria: * Pancreas cancer that cannot be removed by surgery OR that has spread to a new site in your body. * You must have one tumor that can be physically measured or scanned by the doctor. * You have not had any chemotherapy, immunotherapy, biologic therapy, or hormonal therapy for pancreas cancer, including 5-FU. * You cannot have any radiation for 4 weeks before starting this study, and you cannot have radiation to the whole pelvis. Exclusion Criteria: * Treatment with any medication or device that has not been approved by regulatory agencies, like the FDA, at the time you enter the study. * Documentation that the cancer has spread to your brain. * Pregnant or breastfeeding. * A second primary cancer. * Unable to stop aspirin or non-steroidal anti-inflammatory agents (like ibuprofen) for 5-8 days.